Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00174603
Other study ID # IRUSQUET305
Secondary ID
Status Terminated
Phase Phase 3
First received September 9, 2005
Last updated December 28, 2007
Start date August 2005
Est. completion date January 2007

Study information

Verified date December 2007
Source Rush University Medical Center
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to examine the mood stabilizing and antipsychotic properties of quetiapine in the treatment of depression by comparing subjects who were randomly assigned to either quetiapine monotherapy, quetiapine and citalopram; or haloperidol and citalopram. We hypothesize that quetiapine monotherapy would have similar effects to the combination of a first generation antipsychotic plus an antidepressant for the treatment of a major depressive episode with psychosis.


Description:

Thus, current practice for treating psychotic depression is to combine an antidepressant with an antipsychotic. However, there are limitations to this approach. The rate of response is still lower than in other forms of major depression (Janicak et al., 2001). The rate of noncompliance is higher in this group; and the incidence of adverse effects related to the antipsychotic is increased (Janicak et al., 2001). As a result, studies have examined alternative treatments. The present study proposes to examine quetiapine's antipsychotic and mood stabilizing properties for the treatment of a major depressive disorder with psychotic features Subjects will be randomized to either quetipine monotherapy, quetiapine and citalopram; or haloperidol and citalopram.


Recruitment information / eligibility

Status Terminated
Enrollment 60
Est. completion date January 2007
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Male and female subjects between the ages of 18 to 75 years.

- A Structured Clinical Interview for the DSM-IV (SCID) derived diagnosis of major depression with psychosis, single or recurrent episode (unipolar or bipolar).

- Subjects may have an anxiety disorder or an additional mood disorder such as dysthymia.

- Baseline 24-item Hamilton Depression Rating Scale (HDRS) score of greater than or equal to 21.

- A baseline Positive and Negative Syndrome Scale (PANSS) score of greater than or equal to 4 on at least one of the 4 psychosis items.

- Women of childbearing potential must agree to practice a medically accepted means of contraception.

- Length of current episode no longer than 3 months.

Exclusion Criteria:

- Pregnant or lactating women

- Women of child-bearing age who refuse a pregnancy test or who refuse to use a contraceptive technique when sexually active.

- Persons with other psychotic disorders; a mood disorder due to a general medical condition or substance-induced; substance dependence disorder in the last 6 months; substance abuse in the last 6 months or a dementing disorder are excluded.

- Persons with serious, unstable medical illnesses.

- Subjects who have been intolerant or nonresponsive to adequate trials of quetiapine, haloperidol and/or citalopram.

- Subjects who have received an injectable decanoate medication within 1 half life of the medication (i.e, 4 weeks for haloperidol or 2 weeks for fluphenazine).

- Subjects who have received fluoxetine within 4 weeks prior to randomization.

- Subjects who have received aripiprazole within 2 weeks prior to randomization.

- Subjects who have been treated with ECT within the last 6 months.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
quetiapine


Locations

Country Name City State
United States Rush University Medical Center Chicago, Illinois

Sponsors (2)

Lead Sponsor Collaborator
Rush University Medical Center AstraZeneca

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Hamilton Rating Scale for Depression
Secondary Positive and Negative Syndrome Scale
Secondary Young Mania Rating Scale
Secondary Barnes Akathisia Scale
Secondary Simpson Angus Scale
Secondary Clinical Global Impressions
See also
  Status Clinical Trial Phase
Terminated NCT00174590 - Treatment of Major Depressive Disorder With Psychotic Features. Phase 3
Completed NCT01259427 - Reducing Internalized Stigma in People With Serious Mental Illness Phase 2
Terminated NCT01624831 - Social Cognition in Longstanding Psychosis
Recruiting NCT05877716 - EPI-MINN: Targeting Cognition and Motivation - National N/A
Recruiting NCT04497857 - Academic-Community EPINET (AC-EPINET) N/A
Completed NCT01196286 - Multifamily Psychoeducation and Cognitive Remediation for Recent-Onset Psychosis N/A
Recruiting NCT04004416 - Multi-modal Assessment of Gamma-aminobutyric Acid (GABA) Function in Psychosis Phase 4
Completed NCT01570972 - Mediators and Moderators of Treatment Outcome in Recent-Onset Psychosis N/A